title: Pelvic perfusion for locally recurrent unresectable rectal tumors.
abstract: OBJECTIVE
  Pelvic perfusion evolved as a palliative and curative treatment modality for advanced pelvic tumors and literature data support its use in different steps of the disease.
  
  
  METHODS
  15 patients with recurrent rectal tumor, without any systemic metastases were included in the study. Mean age was 49.7 years, 12 males, 3 females. Mean survival was 18 months.
  
  
  RESULTS
  15 unresectable rectal cancer patients were included in this study. Three (20%) complete response, 6 (40%) partial response, 2 stable disease (13.3%) and 4 (26.7%) progression were seen after pelvic perfusion. Mean survival is 26.54 months after perfusion (median=10). In multivariate analysis response rate to isolated perfusion and tumor size are significant factors effecting survival (p<0.05). The patients who did not receive chemotherapy after detection of pelvic recurrence did better (p=0.0086). Response to isolated pelvic perfusion (IPP) is an important factor for survival of locally advanced rectal tumors in log-rank test (p=0.0001).
  
  
  CONCLUSIONS
  Isolated pelvic perfusion is a good alternative for non-resectable pelvic malignancies and should be considered as an important part of the multidisciplinary approach for these tumors.
authors.affiliation: Department of Surgery, Section of Surgical Oncology, Ankara University Medical School, Ankara, Turkey. ekremunal@hotmail.com
authors.forename: Ali Ekrem
authors.initials: AE
authors.lastname: Unal
authors.forename: Sancar
authors.initials: S
authors.lastname: Bayar
authors.forename: Mesut
authors.initials: M
authors.lastname: Tez
authors.forename: Erdal
authors.initials: E
authors.lastname: Gocmen
authors.forename: Hilmi
authors.initials: H
authors.lastname: Kocaoglu
authors.forename: Hikmet
authors.initials: H
authors.lastname: Akgul
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000556:secondary*; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D010386:Pelvic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000556:secondary*; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate
chemical_list: D016685:Mitomycin; D002945:Cisplatin; D005472:Fluorouracil